Bio-Rad Laboratories Competitors

Bio-Rad Laboratories (NYSE:BIO.B) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

0.1% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bio-Rad Laboratories and Illumina's net margins, return on equity and return on assets.

Volatility and Risk

Bio-Rad Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Bio-Rad Laboratories and Illumina's gross revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bio-Rad Laboratories and Illumina, as reported by MarketBeat.com.

Illumina has a consensus target price of $370.5789, suggesting a potential downside of 7.12%. Given Illumina's higher probable upside, analysts clearly believe Illumina is more favorable than Bio-Rad Laboratories.

Summary

Illumina beats Bio-Rad Laboratories on 9 of the 12 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Volatility and Risk

Agilent Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Profitability

This table compares Agilent Technologies and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Agilent Technologies and Bio-Rad Laboratories' gross revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has lower revenue, but higher earnings than Agilent Technologies.

Insider and Institutional Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Agilent Technologies and Bio-Rad Laboratories, as reported by MarketBeat.com.

Agilent Technologies currently has a consensus price target of $104.70, suggesting a potential downside of 20.24%. Given Agilent Technologies' higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Summary

Agilent Technologies beats Bio-Rad Laboratories on 7 of the 12 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mettler-Toledo International and Bio-Rad Laboratories, as reported by MarketBeat.com.

Mettler-Toledo International presently has a consensus target price of $971.3750, indicating a potential downside of 20.30%. Given Mettler-Toledo International's higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Valuation and Earnings

This table compares Mettler-Toledo International and Bio-Rad Laboratories' revenue, earnings per share and valuation.

Bio-Rad Laboratories has lower revenue, but higher earnings than Mettler-Toledo International.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 0.1% of Bio-Rad Laboratories shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Mettler-Toledo International and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 9 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO.B) and 10x Genomics (NASDAQ:TXG) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and 10x Genomics, as provided by MarketBeat.com.

10x Genomics has a consensus target price of $181.4444, indicating a potential downside of 3.65%. Given 10x Genomics' higher probable upside, analysts plainly believe 10x Genomics is more favorable than Bio-Rad Laboratories.

Institutional and Insider Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 68.8% of 10x Genomics shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 13.3% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bio-Rad Laboratories has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Rad Laboratories and 10x Genomics' gross revenue, earnings per share and valuation.

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics.

Profitability

This table compares Bio-Rad Laboratories and 10x Genomics' net margins, return on equity and return on assets.

Summary

Bio-Rad Laboratories beats 10x Genomics on 7 of the 12 factors compared between the two stocks.

Waters (NYSE:WAT) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Waters and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Insider and Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 0.1% of Bio-Rad Laboratories shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Waters and Bio-Rad Laboratories, as reported by MarketBeat.

Waters presently has a consensus price target of $224.20, suggesting a potential downside of 26.98%. Given Waters' higher possible upside, analysts clearly believe Waters is more favorable than Bio-Rad Laboratories.

Valuation & Earnings

This table compares Waters and Bio-Rad Laboratories' top-line revenue, earnings per share and valuation.

Bio-Rad Laboratories has lower revenue, but higher earnings than Waters.

Volatility and Risk

Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

Waters beats Bio-Rad Laboratories on 8 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO.B) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Risk & Volatility

Bio-Rad Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Avantor has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.

Profitability

This table compares Bio-Rad Laboratories and Avantor's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Bio-Rad Laboratories and Avantor, as provided by MarketBeat.com.

Avantor has a consensus target price of $29.7941, suggesting a potential downside of 9.63%. Given Avantor's higher probable upside, analysts clearly believe Avantor is more favorable than Bio-Rad Laboratories.

Institutional & Insider Ownership

0.1% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 84.8% of Avantor shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.9% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Avantor's gross revenue, earnings per share and valuation.

Bio-Rad Laboratories has higher earnings, but lower revenue than Avantor.

Summary

Avantor beats Bio-Rad Laboratories on 8 of the 12 factors compared between the two stocks.